Canaccord Genuity Group Cuts Ventyx Biosciences (NASDAQ:VTYX) Price Target to $14.00

Ventyx Biosciences (NASDAQ:VTYX) had its price objective decreased by Canaccord Genuity Group from $15.00 to $14.00 in a research note issued to investors on Monday morning, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

Other equities research analysts also recently issued reports about the stock. HC Wainwright restated a neutral rating and issued a $6.00 target price on shares of Ventyx Biosciences in a research note on Tuesday, July 30th. Oppenheimer decreased their price objective on Ventyx Biosciences from $12.00 to $10.00 and set an outperform rating for the company in a report on Thursday, June 6th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Ventyx Biosciences presently has an average rating of Moderate Buy and an average target price of $8.29.

Ventyx Biosciences Stock Down 2.1 %

Shares of VTYX stock opened at $1.91 on Monday. The firm has a market cap of $134.65 million, a price-to-earnings ratio of -0.59 and a beta of 0.39. Ventyx Biosciences has a 52-week low of $1.87 and a 52-week high of $38.20. The company’s 50 day moving average is $2.52 and its 200 day moving average is $4.16.

Ventyx Biosciences (NASDAQ:VTYX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.12. Analysts anticipate that Ventyx Biosciences will post -2.31 EPS for the current fiscal year.

Institutional Trading of Ventyx Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in VTYX. SG Americas Securities LLC purchased a new position in shares of Ventyx Biosciences during the 2nd quarter valued at about $32,000. Tower Research Capital LLC TRC raised its position in Ventyx Biosciences by 1,424.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 19,927 shares of the company’s stock valued at $49,000 after acquiring an additional 18,620 shares in the last quarter. Federated Hermes Inc. acquired a new position in Ventyx Biosciences in the fourth quarter valued at approximately $50,000. Norden Group LLC purchased a new stake in Ventyx Biosciences in the 1st quarter worth approximately $59,000. Finally, American Century Companies Inc. acquired a new stake in shares of Ventyx Biosciences during the 2nd quarter worth approximately $60,000. Institutional investors and hedge funds own 97.88% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.